Advertisement
Advertisement
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
2.93
USDSponsored
-0.01
-0.34%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
2.94
0.00
+0.17%
OKUR Earnings Reports
Positive Surprise Ratio
OKUR beat 13 of 22 last estimates.
59%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$170.00K
/-$0.41
Implied change from Q2 26 (Revenue/ EPS)
--
/+32.26%
Implied change from Q3 25 (Revenue/ EPS)
--
/-62.39%
OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Aug 04, 2026, OKUR reported earnings of -0.31 USD per share (EPS) for Q2 26, beating the estimate of -0.54 USD, resulting in a 43.19% surprise. Revenue reached --, compared to an expected 170.00 thousand, with a -100.00% difference. The market reacted with a +1.46% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.41 USD, with revenue projected to reach 170.00 thousand USD, implying an increase of 32.26% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$0.31, beating estimates by 43.19%, and revenue of $0.00, -100% below expectations.
How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved up 1.46%, changed from $4.10 before the earnings release to $4.16 the day after.
When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 3
analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.41 and revenue of $170.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.